New pooled analysis adds weight to edoxaban's benefits in VTE after orthopaedic surgery
This article was originally published in Scrip
Executive Summary
A pooled analysis of existing Asian data for Daiichi Sankyo's antithrombotic edoxaban has provided further evidence of the efficacy and safety of the oral direct Factor Xa inhibitor in the orthopaedic setting compared with the current standard of care, enoxaparin sodium.